Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-064726
Filing Date
2025-05-07
Accepted
2025-05-06 18:09:52
Documents
73
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rare-20250331.htm   iXBRL 10-Q 2626074
2 EX-10.1 rare-ex10_1.htm EX-10.1 97028
3 EX-31.1 rare-ex31_1.htm EX-31.1 17516
4 EX-31.2 rare-ex31_2.htm EX-31.2 16956
5 EX-32.1 rare-ex32_1.htm EX-32.1 13660
6 GRAPHIC img217772269_0.jpg GRAPHIC 264788
  Complete submission text file 0000950170-25-064726.txt   10005071

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rare-20250331.xsd EX-101.SCH 1071752
76 EXTRACTED XBRL INSTANCE DOCUMENT rare-20250331_htm.xml XML 1678758
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36276 | Film No.: 25918720
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)